anti-miR-221/222 antisense oligonucleotide (Regulus/Sanofi)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameanti-miR-221/222 antisense oligonucleotide (Regulus/Sanofi)
Drug Alias Nameanti-miR-221 antisense oligonucleotide (Regulus)miR-221/222
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAntisense oligonucleotide inhibitors
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegulus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegulus Therapeutics IncIonis Pharmaceuticals IncSanofi +[4] 
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A